The potent and selective inhibitors of BRAF‐mutant kinase vemurafenib (V), dabrafenib (D), and encorafenib (E) have demonstrated an advantage in survival outcomes in untreated BRAFv600 mutant metastatic melanoma (MM) compared with standard chemotherapy (Chapman et al. 2017, 2011). This evidence concerns the gene BRAF and metastatic melanoma.